drugset / Trial / NCT00646750
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy (complete response rate) of Ybritumomab Tiuxetan (Zevalin) administration in the conditioning treatment of patients with refractory large B-cell diffuse lymphoma submitted to autologous transplantation of peripheral blood haematopoietic stem cells.
Timeline
- Start
- 2008-01
- Primary completion
- 2010-02
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ybritumomab Tiuxetan | Unknown | 14.8 mbq/kg | — |
| Background | Cytarabine | Small molecule | 200 mg/m2 | — |
| Background | Etoposide | Small molecule | 200 mg/m2 | — |
| Background | Melphalan | Small molecule | 140 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Background | carmustine | Small molecule | 300 mg/m2 | — |